Vaccine Characterization and Analysis

GLP and GMP vaccine characterisation and bioassay support for vaccine developers and manufacturers including stability studies and release testing

Vaccines are developed either as a prophylactic treatment to prevent future infection or as a therapeutic. A growing number of vaccines today are based on well-defined materials, including vaccines based on purified protein antigens of natural origin or produced by rDNA technology, polysaccharides, semi-synthetic poly- or oligosaccharide-protein conjugates and novel nucleic acid constructs. Other vaccine technology includes viral vector based products or virus-like particles (VLPs) which consist of phospholipid bilayer vesicles and act as a vaccine carrier and an adjuvant.

These products can present challenges for characterization. Our vaccines development support teams apply application a comprehensive suite of methods to evaluate the carbohydrate, lipopolysaccharide, lipid, protein, glycoprotein, and lipoprotein components of vaccines. Our experts provide support for vaccine manufacturers and researchers throughout the vaccine development process including vaccine stability studies and vaccine release testing. Bringing quality and safety to life, we offer Total Quality Assurance expertise to help you to meet and exceed quality, safety and regulatory standards.


Vaccine Analysis Services:  

Need help or have a question? +44 161 721 5247

Need help or have a question?

+44 161 721 5247
+44 161 721 5247